<DOC>
	<DOC>NCT01046422</DOC>
	<brief_summary>The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population</brief_summary>
	<brief_title>Safety Study of BMS-770767 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed with type 2 diabetes with inadequate glycemic control and treated with either diet and exercise alone, or with stable doses (≥ 1500mg/d) of metformin for at least 8 weeks prior to screening HbA1c ≥ 7.0% and ≤ 10.0% with FPG ≤ 240mg/dL (13.3 mmol/dL) Women of childbearing potential History of diabetic ketoacidosis or hyperosmolar nonketotic coma Significant cardiovascular history History of unstable or rapidly progressing renal disease Impaired renal function defined by a serum creatinine &gt; 1.4mg/dL (124 µmol/L) for women and &gt;1.5mg/dL (133 µmol/L) for men Active liver disease and /or significant abnormal liver function defined as AST &gt; 3X ULN and/or ALT &gt; 3XULN and /or serum total bilirubin &gt; 2.0mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>